Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MELK | Q14680 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633251 | 0.85 | ALDH1A1 (0.47) | GRM5SMN1; SMN2FFAR1ALDH1A1MELK | |
| SCHEMBL30574457 | 0.85 | MEN1 (0.48) | GRM5HTTSMN1; SMN2FFAR1FFAR4 | |
| SCHEMBL8993127 | 0.82 | GRM5 (0.52) | GRM5HTTSMN1; SMN2FFAR1FFAR4 | |
| SCHEMBL30469481 | 0.80 | GRM5 (0.69) | GRM5HTTSMN1; SMN2FFAR1FFAR4 | |
| SCHEMBL30469478 | 0.80 | GRM5 (0.69) | GRM5HTTSMN1; SMN2FFAR1FFAR4 | |
| SCHEMBL4562089 | 0.80 | GRM5 (0.69) | GRM5HTTSMN1; SMN2FFAR1FFAR4 | |
| SCHEMBL5174894 | 0.80 | CYP2C19 (0.57) | GRM5HTTSMN1; SMN2FFAR1FFAR4 | |
| SCHEMBL5536022 | 0.80 | GRM5 (0.50) | GRM5HTTSMN1; SMN2FFAR1FFAR4 | |
| SCHEMBL28469408 | 0.80 | GRM5 (0.50) | GRM5HTTSMN1; SMN2FFAR1FFAR4 | |
| SCHEMBL81832 | 0.79 | FFAR1 (0.41) | GRM5HTTSMN1; SMN2FFAR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466790-B | Preparation method of alpha-sulfinylated carbonyl compound | 西北师范大学 | 2024-05-28 | — | — | CN | claimed |
| CN-117466790-A | Preparation method of alpha-sulfinylated carbonyl compound | 西北师范大学 | 2024-01-30 | — | — | CN | claimed |
| CN-117466790-B | Preparation method of alpha-sulfinylated carbonyl compound | 西北师范大学 | 2024-05-28 | — | — | CN | disclosed |
| CN-117466790-A | Preparation method of alpha-sulfinylated carbonyl compound | 西北师范大学 | 2024-01-30 | — | — | CN | disclosed |
| CN-111662147-B | Process for preparing diynes and analogues thereof | 清华大学 | 2021-08-10 | — | — | CN | disclosed |
| CN-111662147-A | Process for preparing diynes and analogues thereof | 清华大学 | 2020-09-15 | — | — | CN | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-2968282-A1 | HISTONE DEMENTHYLASE INHIBITORS | Quanticel Pharmaceuticals Inc (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014164708-A1 | HISTONE DEMENTHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | disclosed |
| US-20110172455-A1 | PROCESS FOR PREPARING CINACALCET AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | IND-SWIFT LABORATORIES LIMITED (IN) | 2011-07-14 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| WO-2010063487-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-06-10 | — | — | WO | disclosed |
| EP-2168944-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
| EP-2168944-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-RE39850-E1 | Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents | METHYLGENE, INC. (CA) | 2007-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172455-A1 | PROCESS FOR PREPARING CINACALCET AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CA9, SI, REN | GRM5 2561/4885HTT 4361/4885SMN1; SMN2 3874/4885 |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | GRM5 1319/4885HTT 3158/4885SMN1; SMN2 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.